Guggenheim raised the firm’s price target on Travere Therapeutics to $41 from $23 and keeps a Buy rating on the shares. Following the conclusion of the PARASOL workshop, the firm has heightened confidence in Filspari’s potential approval for focal segmental glomerulosclerosis, or FSGS, leading it to raise its Filspari FSGS probability of success estimate to 75% from 60%, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TVTX:
- Travere Therapeutics price target raised to $18 from $14 at Barclays
- Travere Therapeutics price target lowered to $22 from $23 at Canaccord
- Travere Therapeutics price target lowered to $17 from $19 at Wedbush
- Travere selloff on trial pause an opportunity, says Citi
- Travere Therapeutics price target lowered to $18 from $19 at BofA